Tilray Brands, Inc. (NASDAQ:TLRY)
| Market Cap | $211.36M-79.1% |
| Revenue (ttm) | $963.10M+15.9% |
| Net Income | -$164.22M+92.4% |
| EPS | -$1.40+93.8% |
| Shares Out | 111.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,870,379 |
| Open | $2.03 |
| Previous Close | $2.07 |
| Day's Range | $1.87 - $2.08 |
| 52-Week Range | $1.87 - $15.70 |
| Beta | 2.05 |
| Analysts | Hold |
| Price Target | $10.00(+429.10%) |
| Earnings Date | Jan 11, 2027 |
About TLRY
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating TLRY in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Jan 11, 2027Earnings report
$TLRY stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of TLRY by members of U.S. Congress
| Brian Jeffrey MastHouse / R | Sale$50.00K – $100.00K | Feb 10, 2021 |
| Brian Jeffrey MastHouse / R | Sale$15.00K – $50.00K | Feb 9, 2021 |
| Brian Jeffrey MastHouse / R | Purchase$15.00K – $50.00K | Nov 6, 2020 |
| Brian Jeffrey MastHouse / R | Sale$15.00K – $50.00K | Feb 4, 2019 |
| Brian Jeffrey MastHouse / R | Purchase$15.00K – $50.00K | Jan 18, 2019 |
Recently reported changes in TLRY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TLRY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TLRY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TLRY Revenue by Segment or Geography
| Marketing and promotion | $15.74M | 42.11% |
| Selling | $13.59M | 36.38% |
| Transaction costs, net | $4.80M | 12.85% |
| Restructuring costs | $2.45M | 6.55% |
| Litigation costs, net of recoveries | $787.00K | 2.11% |
As of: Q3 2026 (Aug 31, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TLRY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TLRY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TLRY
| VALTETFMG Sit Ultra Short ETF | $17.21M |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $14.44M |
| MJAmplify Alternative Harvest ETF | $5.47M |
| HMLSFGlobal X Marijuana Life Sciences Index ETF | $1.75M |
| THCXThe Cannabis ETF | $1.25M |
| VHTVanguard Health Care ETF | $961.88K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TLRY’s recent data — informational, not investment advice
What’s Behind the Score
News check: Tilray raised full-year guidance and marijuana rescheduling provide positive catalysts; mixed analysis on competitive positioning and balance sheet strength.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| SILX | ETFMG Prime 2x Daily Junior Silver Miners ETF | 16.37% |
| MJ | Amplify Alternative Harvest ETF | 7.43% |
| HMLSF | Global X Marijuana Life Sciences Index ETF | 7.26% |
| HMMJ.TO | Global X Marijuana Life Sciences Index ETF | 7.26% |
| THCX | The Cannabis ETF | 5.52% |
| BAD | B.A.D. ETF | 1.93% |
| LOPX | Direxion Low Priced Stock ETF | 1.73% |
| YOLO | AdvisorShares Pure Cannabis ETF | 0.91% |
| VALT | ETFMG Sit Ultra Short ETF | 0.52% |
| VHT | Vanguard Health Care ETF | 0.01% |
| FHLC | Fidelity MSCI Health Care Index ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
